Potential metabolic markers in glaucoma and their regulation in response to hypoxia.
Rupali Vohra, Line Marie Dalgaard, Jeppe Vibaek, Mia Aggergaard Langbøl, Linda Hildegaard Bergersen, Niels Vidiendal Olsen, Bjørnar Hassel, Farrukh Abbas Chaudhry, Miriam Kolko
Summary
Reduced serum levels of lactate and total amino acids were identified as potential markers for NTG.
Abstract
PURPOSE
To assess novel differences in serum levels of glucose, lactate and amino acids in patients with normal-tension glaucoma (NTG) compared to age-matched controls, at baseline and in response to universal hypoxia.
METHODS
Twelve patients diagnosed with NTG and eleven control subjects underwent normobaric hypoxia for 2 hr. Peripheral venous blood samples were taken at baseline, during hypoxia and in the recovery phase. Serum glucose and lactate levels were measured by a blood gas analyser. Amino acids were analysed by high-performance liquid chromatography.
RESULTS
Baseline levels of lactate and total amino acids were significantly lower in patients with NTG compared to healthy controls. No differences were seen in blood glucose levels between the two groups. Lactate levels remained unchanged during hypoxia in the control group, but increased in patients with NTG. In the recovery phase, total amino acid levels were reduced in the control group, whereas no changes were found in patients with NTG.
CONCLUSION
Reduced serum levels of lactate and total amino acids were identified as potential markers for NTG. Moreover, significant differential regulatory patterns of certain amino acids were found in patients with NTG compared to control subjects. Overall, our results suggest a link between systemic energy metabolites and NTG and support a novel understanding of glaucoma as an inner retinal manifestation of a systemic condition.
Keywords
More by Rupali Vohra
View full profile →When Is a Control Not a Control? Reactive Microglia Occur Throughout the Control Contralateral Pathway of Retinal Ganglion Cell Projections in Experimental Glaucoma.
Semaglutide Protects Retinal Ganglion Cells Against Rotenone-Induced Degeneration via Improved Glucose Metabolism.
Discussion
Comments and discussion will appear here in a future update.